Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Abstract

In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• Harvard University US
• Inserm FR
• Ospedale di Parma IT
• Universitäts-Herzzentrum Freiburg-Bad Krozingen DE
• Eli Lilly (United States) US
• Azienda Ospedaliera Ospedale Civile di Legnano IT
• Institute of Cardiology PL
• Bikur Cholim Hospital IL

Related Publications